ArticleJHLT open2026
Temporal trends and post-transplant outcomes in anthracycline-induced cardiomyopathy: A contemporary United Network for Organ Sharing analysis.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: Outcomes after heart transplantation for anthracycline-induced cardiomyopathy (AICM) remain incompletely characterized, particularly compared with idiopathic dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM). Methods: We analyzed adult first-time isolated heart transplant recipients in the Organ Procurement and Transplantation Network/United Network for Organ Sharing registry from January 1, 2000, to September 25, 2025. Recipients were grouped as AICM, idiopathic DCM, or ICM by registry diagnosis. The primary outcome was all-cause post-transplant mortality. Secondary outcomes included graft failure, post-transplant dialysis, stroke, pacemaker implantation, treated rejection, and length of stay. Results: Compared with idiopathic DCM, AICM was not associated with higher adjusted mortality (HR 1.11, 95% CI 0.98-1.25; Conclusions: Among selected adult heart transplant recipients, anthracycline-induced cardiomyopathy was not associated with worse post-transplant survival or graft failure compared with idiopathic DCM. However, AICM recipients had higher adjusted odds of post-transplant dialysis, longer index hospitalization, and a greater burden of malignancy-related death, highlighting the need for individualized oncologic and renal-risk assessment in transplant candidates with prior anthracycline exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.